Immunosenescence: implications for vaccination programs in the elderly

Abstract:

Worldwide, infectious disease is responsible for much of the morbidity and mortality in the elderly. As the number of individuals over the age of 65 increases, the economic and social costs of treating these infections will become a major challenge. Vaccination is the most effective and least costly preventative measure in our arsenal; however, vaccines that are effective in children and young adults are often ineffective in older adults. This is a result of the deterioration in immune function that occurs with age, referred to as immunosenescence. Age-associated changes in leukocyte phenotype and function impair primary vaccine responses and weaken long-lasting memory responses. In this review, we discuss current vaccination approaches in the elderly and strategies to improve responsiveness in older adults, which include increasing vaccine immunogenicity and overcoming the fundamental immune defects that prevent optimal immune responses.

Keywords::

• immunosenescence
• vaccination
• elderly
• influenza
• pneumonia
• zoster

Acknowledgments

Work in the Bowdish lab is funded by the Canadian Institutes of Health Research (CIHR) and is supported by the McMaster Immunology Research Centre and the MG DeGroote Institute for Infectious Disease Research.

Disclosure

DMEB is a Canada Research Chair in Aging and Immunity. AN is supported by a CIHR Canada Graduate Scholarship and the Michael Kamin-Hart Memorial Fund. DL is supported by an Early Researcher Award to DMEB.